

# **CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS**

Manuscript page number (Without Figures): 18 Rate: 6.2 CNY per page

Editing Fee: 111.6 CNY

Figure count: <u>4</u> Figure handling time: <u>120</u> min Rate: <u>1</u> CNY per min

Editing Fee: 120 CNY

XML and PDF converting time: 60 min Rate: 1 CNY per min

Editing Fee: 60 CNY

Manuscript word count: 3882

Total Editing Fee: 291.6 CNY

Scientific Editor: Yu-Jie Ma

Date of signature: 2022/06/14 (month/day/year)

| Item No. |  | Comments |
|----------|--|----------|
|          | Specific items for verification  | Yes=[Y]  |
|          |  | No= [N]  |
|          | General Information of the Manuscript                                  |          |
|          | Name of journal: World Journal of Clinical Cases                       |          |
|          | Manuscript NO.: 76448  |          |
|          | Column: Case Report  |          |
| 1        | Title: Differences in examination results of small anastomotic fistula |          |
| L        | after radical gastrectomy with afterward treatments: A case report     | [Y]      |
|          | Authors: Chen-Yang Lu, Ya-Li Liu, Kui-Jie Liu, Shu Xu,                 |          |
|          | Hong-Liang Yao, Lun Li and Zhu-Shu Guo                                 |          |
|          | <b>Reviewer code:</b> 05142912, 03845518, and 05142912                 |          |
|          | <b>First decision:</b> 2022-05-09 07:32                                |          |
| 2        | Editorial Office's Comments  | [Y]      |



|   | Science Editor: The manuscript has been sent to peer-reviewers for       |     |
|---|--|-----|
|   |  |     |
|   | re-reviewing.  |     |
|   | Company Editor-in-Chief: I recommend the manuscript to be                |     |
|   | published in the World Journal of Clinical Cases.                        |     |
| 3 | The fixed headings are copied.   | [Y] |
|   | The title concisely summarizes the main topic of the study and is        | [Y] |
|   | not too long (no more than 18 words). Words such as 'exploration',       |     |
| 4 | 'research', 'analysis', 'observation', and 'investigation' are avoided.  |     |
|   | The title does not start with 'The' and does not include any Arabic      |     |
|   | numbers or uncommon abbreviations.                                       |     |
| 5 | A short running title is provided (no more than 6 words).                | [Y] |
|   | The authors' full family (sur)names and full/abbreviated first           | [Y] |
| 6 | names are listed on the title page and are consistent with those         |     |
|   | listed in the signed BPG Copyright License Agreement form.               |     |
|   | The 'Author contributions' passage describes the specific                | [Y] |
|   | contribution(s) made by each author. The author's names are listed       |     |
|   | in the following format: full family (sur)name followed by               |     |
|   | abbreviated first and middles names.                                     |     |
|   | <i>e.g.,</i> "Wang CL and Liang L contributed equally to this work; Wang |     |
| 7 | CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the                |     |
|   | research study; Wang CL, Zou CC, Hong F and Wu XM performed              |     |
|   | the research; Xue JZ and Lu JR contributed new reagents and              |     |
|   | analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and        |     |
|   | Wang CL, Liang L and Fu JF wrote the manuscript. All authors             |     |
|   | have read and approve the final manuscript."                             |     |
|   | The 'Supported by' statement describes the source(s) of financial        |     |
| 8 | support and includes the corresponding identification number(s)          | [N] |
|   | and program ID(s) if available, and contains no spelling errors.         |     |



|    | The 'Corresponding author' passage provides the corresponding           | [Y] |
|----|---|-----|
| 9  | author's full first and family (sur)names, abbreviated title (e.g., MD, |     |
|    | PhD), affiliated institute's name and complete postal address           |     |
|    | (including zip code) and e-mail (written in all lowercase), and         |     |
|    | contains no spelling errors.  |     |
|    | The Manuscript Tracking information (i.e., Received, Peer review        | [Y] |
| 10 | started, First decision, Revised, Accepted, Article in press, and       |     |
| 10 | Published online) are provided along with the corresponding editor      |     |
|    | and date for each item, and contain no spelling errors.                 |     |
|    | The Abstract section is formatted according to the article-specific     | [Y] |
|    | style (structured vs unstructured) and word count thresholds, as        |     |
|    | follows:  |     |
|    | Commentary, Frontier, Diagnostic Advances, Medical Ethics,              |     |
|    | Minireview, Review, Therapeutics Advances, and Topic Highlight:         |     |
| 11 | Non-structured abstract that is no less than 200 words.                 |     |
| 11 | Field of Vision, Case Report and Letter to the Editor:                  |     |
|    | Non-structured abstract that is no less than 150 words.                 |     |
|    | Research articles: Structured abstract with subsections for AIM (no     |     |
|    | more than 20 words); METHODS (no less than 80 words); RESULTS           |     |
|    | (no less than 120 words); and CONCLUSION (no more than 26               |     |
|    | words).   |     |
| 12 | The 'Key words' list provides 5-10 keywords that reflect the main       | [Y] |
|    | content of the study. The first letter of each keyword is capitalized,  |     |
|    | and each keyword is separated by a semicolon.                           |     |
| 13 | The "citation" contains authors' names and manuscript title. The        | [Y] |
|    | name of the first author should be typed in bold letters; the family    |     |
|    | (sur) name of all authors should be typed with the first letter         |     |
|    | capitalized, followed by their abbreviated first and middle initials.   |     |
|    | For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick       |     |
|    | Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,         |     |
|    |   |     |



|    | l   |         |
|----|---|---------|
|    | Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes                          |         |
|    | mellitus increases the risk of gastric cancer: A meta-analysis. World J             |         |
|    | Gastroenterol 2019; In press  |         |
|    | The 'Core tip' provides a summary (less than 100 words) of the                      | [Y]     |
| 14 | study that outlines the most innovative and important arguments                     |         |
| 14 | and core contents of the paper and will serve to effectively attract                |         |
|    | readers.  |         |
|    | The 'INTRODUCTION' section clearly describes the relevant                           | [Y]     |
|    | background information for the study. Only the most relevant and                    |         |
|    | current (within the past 5 years) literature is cited, with the                     |         |
|    | exception of rare instances of seminal literature citations. All                    |         |
|    | technical terms and/or abbreviations are explained and/or defined,                  |         |
| 45 | with the full name of abbreviations given upon first appearance in                  |         |
| 15 | the text and the abbreviation presented in parentheses [i.e.,                       |         |
|    | "computed tomography (CT)"]. First-person pronouns (e.g., 'I',                      |         |
|    | 'we') are used appropriately to clearly indicate the work performed                 |         |
|    | by the author(s). When weaknesses of previous studies are                           |         |
|    | described in the text to highlight the innovations related to the                   |         |
|    | current study, the information is presented carefully.                              |         |
|    | The 'MATERIALS AND METHODS' section clearly and accurately                          |         |
| 10 | describes all materials and methods used to obtain the data                         | 5 × 7 1 |
| 16 | presented in the article and is adequate for a reader to repeat the                 | [N]     |
|    | study.  |         |
|    | The 'RESULTS' section concisely describes the observational and                     |         |
|    | experimental results. Representative data and data that have                        |         |
|    | scientific significance are emphasized. Data is presented in either                 |         |
| 17 | the text, a table or figure ( <i>i.e.</i> , chart, diagram, graph or image), but is | [Y]     |
|    | not repeated among each. Information presented in the tables and                    |         |
|    | figures clearly describes the trends, meaning, and inferences.                      |         |
|    | Results described in textual form are accurate, concise and clear.                  |         |
|    | 1   |         |



| 18 | Statistical symbols are accurate. Statistical significance is expressed                   |     |
|----|---|-----|
|    | as ${}^{a}P < 0.05$ , ${}^{b}P < 0.01$ ( $P > 0.05$ usually does not need to be denoted). |     |
|    | If there are other series of <i>P</i> values, $^{c}P < 0.05$ and $^{d}P < 0.01$ are used, | [N] |
|    | and a third series of <i>P</i> values is expressed as $^{e}P < 0.05$ and $^{f}P < 0.01$ . |     |
|    | Statistical data is expressed as mean $\pm$ SD or mean $\pm$ SE.                          |     |
|    | The 'DISCUSSION' section (1) describes the main purpose and                               |     |
|    | hypothesis of the study; (2) summarizes the most important results;                       |     |
|    | (3) illustrates and explains the results (but does not simply repeat                      |     |
| 10 | the data) and draws conclusions or inferences based on the results;                       |     |
| 19 | (4) points out the limitations of the study and their impact on the                       | [Y] |
|    | results, as well as proposes further advice on future research                            |     |
|    | topic(s) or direction(s); and (5) describes the theoretical significance                  |     |
|    | and practical value of the findings.  |     |
|    | The 'ACKNOWLEDGEMENTS' section expresses gratitude to any                                 |     |
|    | individuals or organizations for technical support (i.e., providing                       |     |
|    | instrumentation, equipment or experimental materials, and/or                              |     |
| 20 | assistance in experimental work), non-technical services (i.e., useful                    | [Y] |
|    | inspiration, suggestions, guidance, or review), and/or any other                          |     |
|    | auxiliary work.   |     |
|    | The 'ARTICLE HIGHLIGHTS' section provides comments for                                    |     |
| 21 | original articles in accordance with the specified format.                                | [N] |
|    | The 'REFERENCES' section lists the references in the Vancouver                            | [Y] |
|    | style. This style uses Arabic numeral in-text citations based on the                      |     |
|    | order of the first appearance of a source in the text. For citations                      |     |
| 22 | where the author's name is indicated in the text, a superscript                           |     |
|    | number should be placed following the name ( <i>i.e.,</i> "Pang <i>et al</i> "). For      |     |
|    | citations where no author is indicated, a superscript number should                       |     |
|    | be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup>         |     |
|    | reported", "Pan et al <sup>[2-5]</sup> indicated"; "PCR has a high                        |     |
|    | sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the                  |     |
|    | 1   |     |



|    | reference number is described in the text; for example, "The   |     |
|----|--|-----|
|    | experimental method used has been described in reference [8]." The   |     |
|    | style of reference citations in tables is the same as that in the text   |     |
|    | (e.g., Pan et al <sup>[2-5]</sup> , please see reference [8]).   |     |
|    |  |     |
|    |  |     |
|    |  |     |
|    |  |     |
|    |  |     |
|    | Journal references have been verified to ensure that there are no  | [Y] |
|    | duplicate references and that the PMID numbers are correct. For  |     |
|    | references not yet included in PubMed: the name of Chinese   |     |
| 22 | journals is spelled out using Chinese Pinyin, with the first letter of   |     |
| 23 | each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of   |     |
|    | journals in other languages are listed according to indexing   |     |
|    | information retrieved from Google. Book references are presented   |     |
|    | with all the information relevant to the electronic version.   |     |
|    | The number of cited references is appropriate for the article type, as   | [Y] |
|    | follows:   |     |
| 24 | <u>Commentary:</u> no less than 50;  |     |
| 24 | <u>Review:</u> no less than 100;   |     |
|    | <u>Article:</u> no less than 30/26;  |     |
|    | Case Report and Letter to the Editor: no less than 1.  |     |
|    | The ethics-related statements are provided in accordance with the  | [Y] |
| 25 | manuscript type (e.g., Manuscript NoInstitutional review board   |     |
|    | statement, Manuscript NoAnimal care and use statement, etc.).  |     |
|    | The names of the peer reviewers and the scientific editor are present  | [Y] |
| 26 | at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang  |     |
|    | JL).   |     |
|    | Review: no less than 100;Article: no less than 30/26;Case Report and Letter to the Editor: no less than 1.The ethics-related statements are provided in accordance with the<br>manuscript type (e.g., Manuscript NoInstitutional review board<br>statement, Manuscript NoAnimal care and use statement, etc.).The names of the peer reviewers and the scientific editor are present<br>at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang |     |



| 27The order and numerical labeling of tables and figures is consistent<br>with their appearance and presentation in the text. Symbols in<br>tables (e.g., +, -, ×, +, +) correctly correspond to the definitions in the<br>footnotes. Only one legend is provided for each multi-panel figure<br>consisting of color graphs, black and white graphs, or line graphs<br>that depicts data of the same theme. For example: Figure 1<br>Pathological changes in atrophic gastritis tissue before and after<br>treatment. A:; B:; C:; D:; F:, F:28Split pictures include flow charts, line graphs, histograms, and<br>graphs including text. Unsplit pictures include meta-analysis<br>diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript<br>according to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]30The responses to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870-Review);<br>DAnswering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGinical trial<br>registration statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board[Y]32NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement (file<br>name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board[Y]   |    |  |     |
|--|----|--|-----|
| 27tables (e.g., +, -, ×, +, *) correctly correspond to the definitions in the<br>footnotes. Only one legend is provided for each multi-panel figure<br>consisting of color graphs, black and white graphs, or line graphs<br>that depicts data of the same theme. For example: Figure 1<br>Pathological changes in atrophic gastritis tissue before and after<br>treatment. A:, B:, C:, D:, F:28Split pictures include flow charts, line graphs, histograms, and<br>graphs including text. Unsplit pictures include meta-analysis<br>diagrams, PCR amplification curves, and survival curves.29The author(s) highlighted the changes made to the manuscript<br>according to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.30The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870-Review).31The letter of peer-reviewers' comments is provided (file name:<br>Manuscript NoPeer-review(s); e.g., 870-Answering reviewers).32The response letter is provided (file name: Manuscript<br>NoAnswering reviewers), e.g., 870-Answering reviewers).32The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form   | 27 | The order and numerical labeling of tables and figures is consistent                       | [Y] |
| 27       footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B; C; D; E; F         28       Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.       [Y]         29       The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.       [Y]         30       The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).       [Y]         31       The letter of peer-reviewers' comments is provided (file name: Manuscript NoReview; e.g., 870-Review).       [Y]         31       The response letter is provided (file name: Manuscript NoAnswering reviewers).       [Y]         32       The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoBiostatistics statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form   |    | with their appearance and presentation in the text. Symbols in                             |     |
| <ul> <li>27 consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:</li> <li>28 Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.</li> <li>29 The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.</li> <li>30 The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.</li> <li>31 The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).</li> <li>31 The letter of peer-reviewers' comments is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).</li> <li>32 The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form</li> </ul>  |    | tables ( <i>e.g.</i> , +, -, ×, $\div$ , *) correctly correspond to the definitions in the |     |
| consisting of color graphs, black and white graphs, or line graphs<br>that depicts data of the same theme. For example: Figure 1<br>Pathological changes in atrophic gastritis tissue before and after<br>treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and<br>graphs including text. Unsplit pictures include meta-analysis<br>diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript<br>according to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name:<br>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br>The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript<br>NoGinical trial<br>registration statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form   |    | footnotes. Only one legend is provided for each multi-panel figure                         |     |
| Pathological changes in atrophic gastriits tissue before and after<br>treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and<br>graphs including text. Unsplit pictures include meta-analysis<br>diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript<br>according to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]30The responses to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870-Review).[Y]31The letter of peer-reviewers' comments is provided (file name:<br>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br>The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement (file<br>name: Manuscript NoClinical trial<br>registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form  |    | consisting of color graphs, black and white graphs, or line graphs                         |     |
| treatment. A:; B:; C:; D:; E:; F:Split pictures include flow charts, line graphs, histograms, and<br>graphs including text. Unsplit pictures include meta-analysis<br>diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript<br>according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870- Review).[Y]31The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement); (5) Institutional review board approval form   |    | that depicts data of the same theme. For example: Figure 1                                 |     |
| Split pictures include flow charts, line graphs, histograms, and<br>graphs including text. Unsplit pictures include meta-analysis<br>diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript<br>according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870- Review).[Y]31The response letter is provided (file name: Manuscript<br>NoReview; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript<br>NoBiostatistics review certificate (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form  |    | Pathological changes in atrophic gastritis tissue before and after                         |     |
| 28graphs including text. Unsplit pictures include meta-analysis<br>diagrams, PCR amplification curves, and survival curves.29The author(s) highlighted the changes made to the manuscript<br>according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name:<br>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br>The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>MoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form   |    | treatment. A:; B:; C:; D:; E:; F:  |     |
| Citered of the set of the se |    | Split pictures include flow charts, line graphs, histograms, and                           | [Y] |
| 29The author(s) highlighted the changes made to the manuscript<br>according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870- Review).<br>The letter of peer-reviewers' comments is provided (file name:<br>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br>The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form   | 28 | graphs including text. Unsplit pictures include meta-analysis                              |     |
| 291000000000000000000000000000000000000  |    | diagrams, PCR amplification curves, and survival curves.                                   |     |
| according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with<br>the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name:<br>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br>The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>MoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form  | 20 | The author(s) highlighted the changes made to the manuscript                               | [Y] |
| 3011the changes made to the manuscript.[Y]The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name:<br>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br>The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoClinical trial<br>registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form  | 29 | according to the peer-reviewers' comments.   |     |
| the changes made to the manuscript.[Y]The revised manuscript is provided (file name: Manuscript<br>NoReview; e.g., 870- Review).31The letter of peer-reviewers' comments is provided (file name:<br>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br>The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form   | 20 | The responses to the peer-reviewers' comments are consistent with                          | [Y] |
| <ul> <li>NoReview; e.g., 870- Review).</li> <li>The letter of peer-reviewers' comments is provided (file name:<br/>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).</li> <li>The response letter is provided (file name: Manuscript<br/>NoAnswering reviewers; e.g., 870-Answering reviewers).</li> <li>The related ethics and relevant documents are provided, such as (1)<br/>Approved grant application form(s) or funding agency copy of any<br/>approval document(s) (file name: Manuscript NoGrant application<br/>form(s)); (2) Biostatistics review certificate (file name: Manuscript</li> <li>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br/>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br/>trial registration statement); (5) Institutional review board approval form</li> </ul>  | 30 | the changes made to the manuscript.  |     |
| <ul> <li>The letter of peer-reviewers' comments is provided (file name:<br/>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br/>The response letter is provided (file name: Manuscript<br/>NoAnswering reviewers; e.g., 870-Answering reviewers).</li> <li>The related ethics and relevant documents are provided, such as (1)<br/>Approved grant application form(s) or funding agency copy of any<br/>approval document(s) (file name: Manuscript NoGrant application<br/>form(s)); (2) Biostatistics review certificate (file name: Manuscript</li> <li>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br/>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br/>trial registration statement); (5) Institutional review board approval form</li> </ul>  |    | The revised manuscript is provided (file name: Manuscript                                  | [Y] |
| <ul> <li>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).<br/>The response letter is provided (file name: Manuscript<br/>NoAnswering reviewers; e.g., 870-Answering reviewers).</li> <li>The related ethics and relevant documents are provided, such as (1)<br/>Approved grant application form(s) or funding agency copy of any<br/>approval document(s) (file name: Manuscript NoGrant application<br/>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br/>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br/>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br/>trial registration statement (file name: Manuscript NoClinical trial<br/>registration statement); (5) Institutional review board approval form</li> </ul>   |    | NoReview; e.g., 870- Review).  |     |
| Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).The response letter is provided (file name: Manuscript<br>NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1)<br>Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement); (5) Institutional review board approval form  | 21 | The letter of peer-reviewers' comments is provided (file name:                             |     |
| NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1)Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript32NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form   | 51 | Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).                                    |     |
| The related ethics and relevant documents are provided, such as (1)[Y]Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript32NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form  |    | The response letter is provided (file name: Manuscript                                     |     |
| Approved grant application form(s) or funding agency copy of any<br>approval document(s) (file name: Manuscript NoGrant application<br>form(s)); (2) Biostatistics review certificate (file name: Manuscript<br>NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form  |    | NoAnswering reviewers; e.g., 870-Answering reviewers).                                     |     |
| <ul> <li>approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form</li> </ul>   |    | The related ethics and relevant documents are provided, such as (1)                        | [Y] |
| <ul> <li>form(s)); (2) Biostatistics review certificate (file name: Manuscript</li> <li>NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form</li> </ul>  |    | Approved grant application form(s) or funding agency copy of any                           |     |
| 32 NoBiostatistics statement); (3) Conflict-of-interest statement (file<br>name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form   |    | approval document(s) (file name: Manuscript NoGrant application                            |     |
| name: Manuscript NoConflict-of-interest statement); (4) Clinical<br>trial registration statement (file name: Manuscript NoClinical trial<br>registration statement); (5) Institutional review board approval form  | 32 | form(s)); (2) Biostatistics review certificate (file name: Manuscript                      |     |
| trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form   |    | NoBiostatistics statement); (3) Conflict-of-interest statement (file                       |     |
| registration statement); (5) Institutional review board approval form  |    | name: Manuscript NoConflict-of-interest statement); (4) Clinical                           |     |
|  |    | trial registration statement (file name: Manuscript NoClinical trial                       |     |
| or document (file name: Manuscript NoInstitutional review board  |    | registration statement); (5) Institutional review board approval form                      |     |
|  |    | or document (file name: Manuscript NoInstitutional review board                            |     |



|    | statement) (() Institutional end 1 1 1   |     |
|----|--|-----|
|    | statement); (6) Institutional animal care and use committee                      |     |
|    | approval form or document (file name: Manuscript                                 |     |
|    | NoInstitutional animal care and use committee statement), and (7)                |     |
|    | Signed informed consent form(s) or document(s) (file name:                       |     |
|    | Manuscript NoInformed consent statement).  |     |
|    | All authors signed the BPG Copyright license agreement form (file                | [Y] |
| 33 | name: Manuscript NoCopyright license agreement; <i>e.g.</i> ,                    |     |
|    | 870-Copyright license agreement).  |     |
|    | The language certificate provided by authors who are non-native                  | [Y] |
| 34 | speakers of English meets the BPG requirements (file name:                       |     |
|    | Manuscript NoLanguage certificate; <i>e.g.</i> , 870-Language certificate).      |     |
|    | The photos licensed in the Agreement for Use of Personal Photos                  | [N] |
| 25 | are consistent with those in the paper (file name: Manuscript                    |     |
| 35 | NoAgreement for use of personal photos; e.g., 870-Agreement for                  |     |
|    | use of personal photos).   |     |
|    | This document (Checklist of Responsibilities for Scientific Editors)             | [Y] |
| 36 | has been saved under the file name: manuscript NoScientific                      |     |
|    | editor work list (e.g., 870-Scientific editor work list).                        |     |
|    | A CrossCheck investigation (an effective tool for detecting unoriginal           | [Y] |
|    | content, enabling our editors to preserve the journal's integrity and            |     |
|    | the authors' copyright) has been performed for the manuscript via                |     |
|    | the website: http://www.ithenticate.com/. The results document                   |     |
|    | contains the following information for the manuscript: "Name of                  |     |
| 37 | journal", "Manuscript No.", "Columns", "Title" and "Author list".                |     |
|    | The Figure of the <i>CrossCheck</i> results is saved in JPEG format (.jpg) at    |     |
|    | 1440 $\times$ 680 pixel resolution. The PDF of the <i>CrossCheck</i> results has |     |
|    | been saved under the file name: manuscript No CrossCheck report                  |     |
|    | (e.g., 870-CrossCheck report). The Google searches have also been                |     |
|    | performed to further ensure publication of original content.                     |     |
| 38 | The text of the manuscript is typed in Book Antiqua font, 12 pt, with            | [Y] |
| L  | 1  |     |



|  | 1.5 line spacing.   |  |
|--|---|--|
| Responsibilities<br>of scientific<br>editors | The primary responsibilities of our scientific editors include carefully checking the entire manuscript and all accompanying materials for: (1) errors in spelling, grammar, punctuation and wording; (2) suitability of tables, figures, figure data and legends; (3) accurate and appropriate presentation of symbols ( <i>e.g.</i> +, -, ×, ÷, %, *) in tables and figures; and (4) complete and comprehensive revision of the manuscript  |  |
|  | according to the reviewers' comments.   |  |
| Publication<br>process                       | Manuscript reception and registration $\rightarrow$ Initial review by scientific editor $\rightarrow$ Peer<br>review $\rightarrow$ End of peer review $\rightarrow$ First round of meeting evaluation $\rightarrow$ To be<br>accepted $\rightarrow$ Revision by the author(s) $\rightarrow$ Second round of meeting evaluation $\rightarrow$ To be<br>accepted/revised/rejected $\rightarrow$ Final review by the Editor-in-Chief (final quality<br>control for academic content and language quality) $\rightarrow$ Final acceptance and charging<br>of publication fee $\rightarrow$ Language editing $\rightarrow$ Production $\rightarrow$ Proofreading by scientific<br>editor $\rightarrow$ Proofreading by deputy editor $\rightarrow$ Final review by Editor-in-Chief $\rightarrow$ Release<br>of online open-access papers in electronic form on the BPG website $\rightarrow$ Release of<br>online papers on PubMed Central $\rightarrow$ Delivery of high-quality PDF reprints to the<br>author(s) $\rightarrow$ End of the publication process. |  |